18F-FDG-PET/CT in malignant mesothelioma

Chiara Fuccio, Elena Giulia Spinapolice, Alice Ferretti, Paolo Castellucci, Maria Cristina Marzola, Giuseppe Trifirò, Domenico Rubello

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

It is well known the useful role of 18F-FDG-PET/CT for differential diagnosis between benign and malignant disease, for staging, for monitoring response and for prognosis regarding mesothelioma. Recently, literature was enriched with new interesting studies regarding the potential applications of 18F-FDG-PET/CT in this field. The purpose of this review is to evaluate articles published on line (PubMed) from January 2011 until October 2012 in order to obtain an overview of recent progress of molecular imaging in malignant mesothelioma. The main topics concern the use of 18F-FDG-PET/CT in radiation therapy planning, monitoring of treatment (surgery/chemotherapy) response and prognosis assessment.

Original languageEnglish
Pages (from-to)539-542
Number of pages4
JournalBiomedicine and Pharmacotherapy
Volume67
Issue number6
DOIs
Publication statusPublished - Jul 2013

Fingerprint

Fluorodeoxyglucose F18
Molecular Imaging
Mesothelioma
PubMed
Differential Diagnosis
Radiotherapy
Drug Therapy
Malignant Mesothelioma
Therapeutics

Keywords

  • F-FDG-PET/CT
  • Malignant mesothelioma
  • Prognosis
  • Radiation therapy planning
  • Treatment response

ASJC Scopus subject areas

  • Pharmacology
  • Medicine(all)

Cite this

Fuccio, C., Spinapolice, E. G., Ferretti, A., Castellucci, P., Marzola, M. C., Trifirò, G., & Rubello, D. (2013). 18F-FDG-PET/CT in malignant mesothelioma. Biomedicine and Pharmacotherapy, 67(6), 539-542. https://doi.org/10.1016/j.biopha.2013.01.008

18F-FDG-PET/CT in malignant mesothelioma. / Fuccio, Chiara; Spinapolice, Elena Giulia; Ferretti, Alice; Castellucci, Paolo; Marzola, Maria Cristina; Trifirò, Giuseppe; Rubello, Domenico.

In: Biomedicine and Pharmacotherapy, Vol. 67, No. 6, 07.2013, p. 539-542.

Research output: Contribution to journalArticle

Fuccio, C, Spinapolice, EG, Ferretti, A, Castellucci, P, Marzola, MC, Trifirò, G & Rubello, D 2013, ' 18F-FDG-PET/CT in malignant mesothelioma', Biomedicine and Pharmacotherapy, vol. 67, no. 6, pp. 539-542. https://doi.org/10.1016/j.biopha.2013.01.008
Fuccio C, Spinapolice EG, Ferretti A, Castellucci P, Marzola MC, Trifirò G et al. 18F-FDG-PET/CT in malignant mesothelioma. Biomedicine and Pharmacotherapy. 2013 Jul;67(6):539-542. https://doi.org/10.1016/j.biopha.2013.01.008
Fuccio, Chiara ; Spinapolice, Elena Giulia ; Ferretti, Alice ; Castellucci, Paolo ; Marzola, Maria Cristina ; Trifirò, Giuseppe ; Rubello, Domenico. / 18F-FDG-PET/CT in malignant mesothelioma. In: Biomedicine and Pharmacotherapy. 2013 ; Vol. 67, No. 6. pp. 539-542.
@article{77a3bbbab96b4665b97da7c020e6653d,
title = "18F-FDG-PET/CT in malignant mesothelioma",
abstract = "It is well known the useful role of 18F-FDG-PET/CT for differential diagnosis between benign and malignant disease, for staging, for monitoring response and for prognosis regarding mesothelioma. Recently, literature was enriched with new interesting studies regarding the potential applications of 18F-FDG-PET/CT in this field. The purpose of this review is to evaluate articles published on line (PubMed) from January 2011 until October 2012 in order to obtain an overview of recent progress of molecular imaging in malignant mesothelioma. The main topics concern the use of 18F-FDG-PET/CT in radiation therapy planning, monitoring of treatment (surgery/chemotherapy) response and prognosis assessment.",
keywords = "F-FDG-PET/CT, Malignant mesothelioma, Prognosis, Radiation therapy planning, Treatment response",
author = "Chiara Fuccio and Spinapolice, {Elena Giulia} and Alice Ferretti and Paolo Castellucci and Marzola, {Maria Cristina} and Giuseppe Trifir{\`o} and Domenico Rubello",
year = "2013",
month = "7",
doi = "10.1016/j.biopha.2013.01.008",
language = "English",
volume = "67",
pages = "539--542",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson SAS",
number = "6",

}

TY - JOUR

T1 - 18F-FDG-PET/CT in malignant mesothelioma

AU - Fuccio, Chiara

AU - Spinapolice, Elena Giulia

AU - Ferretti, Alice

AU - Castellucci, Paolo

AU - Marzola, Maria Cristina

AU - Trifirò, Giuseppe

AU - Rubello, Domenico

PY - 2013/7

Y1 - 2013/7

N2 - It is well known the useful role of 18F-FDG-PET/CT for differential diagnosis between benign and malignant disease, for staging, for monitoring response and for prognosis regarding mesothelioma. Recently, literature was enriched with new interesting studies regarding the potential applications of 18F-FDG-PET/CT in this field. The purpose of this review is to evaluate articles published on line (PubMed) from January 2011 until October 2012 in order to obtain an overview of recent progress of molecular imaging in malignant mesothelioma. The main topics concern the use of 18F-FDG-PET/CT in radiation therapy planning, monitoring of treatment (surgery/chemotherapy) response and prognosis assessment.

AB - It is well known the useful role of 18F-FDG-PET/CT for differential diagnosis between benign and malignant disease, for staging, for monitoring response and for prognosis regarding mesothelioma. Recently, literature was enriched with new interesting studies regarding the potential applications of 18F-FDG-PET/CT in this field. The purpose of this review is to evaluate articles published on line (PubMed) from January 2011 until October 2012 in order to obtain an overview of recent progress of molecular imaging in malignant mesothelioma. The main topics concern the use of 18F-FDG-PET/CT in radiation therapy planning, monitoring of treatment (surgery/chemotherapy) response and prognosis assessment.

KW - F-FDG-PET/CT

KW - Malignant mesothelioma

KW - Prognosis

KW - Radiation therapy planning

KW - Treatment response

UR - http://www.scopus.com/inward/record.url?scp=84880934955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880934955&partnerID=8YFLogxK

U2 - 10.1016/j.biopha.2013.01.008

DO - 10.1016/j.biopha.2013.01.008

M3 - Article

VL - 67

SP - 539

EP - 542

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

IS - 6

ER -